Pfizer vaccine appears effective against virus mutations, study finds

Scientists used blood samples from 20 people who received the Pfizer vaccine, made by Pfizer and its German partner BioNTech, during a large study of shots.



The COVID-19 vaccine developed by Pfizer Inc. and its German partner BioNTech appears to work against one of the most infectious mutations in the highly transmissible variants of coronavirus discovered in the U.K. and South Africa, according to a laboratory study.

New research suggests that the Pfizer vaccine has been effective against the N501Y mutation of the novel coronavirus. The study has been conducted by Pfizer along with researchers from the University of Texas Medical Branch.

Pfizer vaccine effective against key mutations, study shows 

Pfizer/BioNTech’s COVID-19 vaccine ‘BNT162b2’ has worked against 16 different virus mutations. “So we’ve now tested 16 different mutations, and none of them have really had any significant impact. That’s the good news. That doesn’t mean that the 17th won’t,” said Phil Dormitzer, one of Pfizer’s top viral vaccine scientists.

Pfizer vaccine coronavirus vaccine COVID-19 virus mutations

Pfizer/BioNTech’s COVID-19 vaccine ‘BNT162b2’ has worked against 16 different virus mutations.

The not-yet peer reviewed study was conducted on blood samples taken from people who had been given the Pfizer vaccine. Its findings are limited as it does not look at the full set of mutations found in either of the new variants of the rapidly developing novel coronavirus.

The researchers plan to run similar tests to see if the vaccine is effective against other coronavirus variants and mutations found in the U.K. and South Africa and hope to have more data within weeks.

Dormitzer noted another mutation found in the South African COVID variant to be dangerous. It may reduce the ability of antibodies to bind the virus and could make Pfizer’s BNT162b2 less effective.

If the virus eventually mutates enough that the vaccine needs tweaking, the new recipe wouldn’t be difficult to develop for Pfizer’s BNT162b2 shot and similar ones. The COVID-19 vaccine is made using a piece of the virus genetic code which is pretty simple to switch. It’s unclear what kind of additional testing FDA made require to make the new recipe.

Dormitzer said this is only the beginning of “ongoing monitoring of virus changes to see if any of them might impact on vaccine coverage.”

Coronavirus Mutation is Worrying 

Scientists have expressed concern that FDA-approved COVID-19 vaccines may still not be able to protect against the new variants, particularly the virus variant found in South Africa.

The Pfizer/BioNTech coronavirus vaccine and the one from Moderna Inc. which use synthetic messenger RNA technology can be quickly tweaked to address new virus mutations if necessary. Scientists have suggested the changes could be made within six weeks.

Drugmakers are keen to test their COVID-19 vaccines against the new variants of the coronavirus that are spreading fast.

Subscribe to the nation’s fastest-growing CEO magazine to get the latest business news delivered to your inbox. 

Avatar
Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

Mercedes unveils EQS electric sedan to rival Tesla’s models

Mercedes unveils EQS electric sedan to rival Tesla’s models

Mercedes-Benz has unveiled a battery-powered luxury car as part of the brand’s flagship S-Class saloon, designed to compete with Tesla. The 2022 Mercedes-Benz EQS is set to relea
2 hours ago
Major US banks report surge in profits for the quarter

Major US banks report surge in profits for the quarter

Three major US banks —JPMorgan Chase & Co., Wells Fargo & Co. and Goldman Sachs Group Inc.—reported earnings results for the first quarter of 2021.
3 hours ago
Bitcoin Price surges above $63,000 ahead of Coinbase IPO

Bitcoin Price surges above $63,000 ahead of Coinbase IPO

Bitcoin price has once again soared over $63,000 USD as the cryptocurrency market braces for the upcoming Coinbase IPO. The San Francisco-based cryptocurrency exchange platform, wh
5 hours ago
Global ETFs reach a new record of $359.2bn in 3 months of ’21

Global ETFs reach a new record of $359.2bn in 3 months of ’21

Global economy recovery is well on its path going by the money being put in the exchange traded funds, especially in the last quarter. A trillion dollars has entered the traded fun
20 hours ago
AppLovin gaming app goes public, valued at $28.6 billion

AppLovin gaming app goes public, valued at $28.6 billion

AppLovin Corp, the Palo Alto, California-based mobile app and gaming company, has priced its initial public offering at $80, which puts the company’s valuation at $28.64 billion.
20 hours ago
JPMorgan earnings beat forecasts amid strengthening US economy

JPMorgan earnings beat forecasts amid strengthening US economy

JPMorgan Chase, the largest bank in America by assets reported favorable results on Wednesday, beating analysts’ estimates on trading revenue. It is the first major bank to repor
2 days ago